KalVista Pharmaceuticals (KALV) Expected to Announce Earnings on Monday

KalVista Pharmaceuticals (NASDAQ:KALV) will likely be announcing its earnings results before the market opens on Monday, March 10th. Analysts expect the company to announce earnings of ($0.89) per share for the quarter.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.01. On average, analysts expect KalVista Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

KalVista Pharmaceuticals Trading Down 0.5 %

NASDAQ KALV opened at $11.92 on Friday. The firm’s fifty day simple moving average is $9.38 and its two-hundred day simple moving average is $10.29. KalVista Pharmaceuticals has a 12-month low of $7.30 and a 12-month high of $15.50. The firm has a market capitalization of $589.06 million, a P/E ratio of -3.27 and a beta of 0.76.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on KALV shares. Bank of America started coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. JMP Securities started coverage on shares of KalVista Pharmaceuticals in a report on Friday, January 31st. They issued an “outperform” rating and a $19.00 price target on the stock. Citizens Jmp raised shares of KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, KalVista Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $23.80.

Insider Activity

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par bought 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 12th. The stock was bought at an average cost of $9.23 per share, for a total transaction of $923,000.00. Following the completion of the transaction, the insider now directly owns 5,217,285 shares of the company’s stock, valued at approximately $48,155,540.55. This trade represents a 1.95 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Paul K. Audhya sold 3,125 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $30,687.50. Following the transaction, the insider now owns 100,334 shares of the company’s stock, valued at $985,279.88. This represents a 3.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have purchased 236,055 shares of company stock valued at $2,162,146 and have sold 18,250 shares valued at $179,160. Corporate insiders own 10.50% of the company’s stock.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).